Speciality drug company Alliance Pharma plc (LON:APH) more than doubled sales after an acquisition last year.
Alliance said its purchase of Sinclair Healthcare Products in December helped it rack up sales of £46.4mln in the six months to June 30 versus £22.8mln a year ago. Sinclair contributed sales of £20.6mln.
The group said it was unlikely to face any potential loss of access to the EU market after the referendum because it already has operations in France, Germany, Italy and Spain.
Chief executive John Dawson said: "Additionally, we do not expect to be adversely affected by the current sterling exchange rate volatility.
"Indeed, if current exchange rates prevail we would expect a modest benefit to our sales and financial performance as we expect trading volumes to continue in line with expectations throughout 2016."
Alliance's three growth brands matched expectations with its largest-selling brand, Kelo-cote, acquired from Sinclair in December 2015, achieving sales of £4.1mln.
Hydromol maintained strong sales growth of 10% in the first half with sales of £3.5mln for the six month period.
Ophthalmology product, MacuShield, acquired in February 2015, made £2mln in the first half versus £1.4mln in the first five months post-acquisition in February 2015.
Alliance said the integration of Sinclair products under the Alliance name was going well.
Activities relating to finance and operations are expected to be largely complete by the end of the third quarter this year and product transfers in the countries are meeting local regulatory timelines.